Thought Leader Select’s Post

Last week, Adam Feuerstein of STAT+ highlighted the complex relationships between patient organizations and pharmaceutical companies. This story emphasizes the need for industry transparency, the independence of advocacy organizations, and the respect for patients contributing to research. Rx4good's Chief Patient Advocate and SVP, Heidi Schultz Adams, shares her insights on our blog. Read more here: https://shorturl.at/9USy7 and sign up for our Good4Patients newsletter to keep up with the latest.

The power of collaboration in healthcare cannot be overstated! Check out our article exploring the partnership between pharmaceutical companies and patient advocacy groups. This enhances patient outcomes and elevates the healthcare experience. #Pharma https://bit.ly/3tmPvP5

If you're considering the viability of a peer advocacy campaign, let's talk about what is possible, what isn't feasible, and how we can help you see the plan through to implementation and execution.

Have you ever heard of peer advocacy? It's a powerful technique that has been used in various industries to achieve rapid adoption and high conversion rates. One of the most successful applications of this technique was in the pharmaceutical industry, where prescribing physicians benefited from the expertise and knowledge of their peers in all phases of a prescription medication's lifecycle. At ByLogic, we believe that peer advocacy is still a highly effective promotional technique that can be applied in many different contexts. So, I'm curious, what do you think? Where do you see peer advocacy being most valuable in today's world? (image Pixabay)

Mega proud to be part of this wonderful initiative. If you are involved in a partnership between biopharmaceutical companies and patient organisations, there is still time to register to take part via the link below!! Partnerships can be in any of the following: 💗Communications 📢 Advocacy 🌐Market Access 🔬Clinical trials 🧪R&D #patientadvocacy #marketaccess #healthcarecommunications

The end is fast approaching! Just 1 day to go until registrations close for the Patient Partnership Index 2023.    If you would like to showcase your involvement in a partnership between biopharmaceutical companies and patient organisations across communications, advocacy, market access, clinical trials, or R&D, register now to submit an entry.     Entries can be led by either partner and will be judged against a bespoke metric developed in partnership with industry and patient organisations to award Gold, Silver or Finalist standards.    Entries to the Index close at 23:55 on Friday 26th April, so register now to receive an entry form, and ensure your partnerships get the recognition they deserve.     The registration form, alongside FAQs and insights from last year’s Index, can be found via the link in comments.    If you have any questions or require further support to get your entry (or entries) in by Friday, please reach out to the PPI team at info@patientpartnershipindex.co.uk.     #clinicaltrials #marketaccess #researchanddevelopment #patientadvocacy #healthcarecommunications 

The Advocate: Supporting the Patient Voice's 2024 US Focused Patient Advocacy Report sheds light on the pharmaceutical industry's efforts to prioritize patient needs and collaborate with advocacy organizations. The report reveals that Johnson & Johnson ranks first for advocacy, commended for its 'willingness to collaborate with patient advocacy organizations beyond funding' and 'taking a holistic approach to building relationships.' Amgen showed significant improvement, praised for being 'highly innovative and forward-thinking' in engaging with patient groups. Pfizer remained consistent, recognized for 'obtaining patient perspectives for advancing care and in helping access to care.' Sanofi garnered appreciation for 'fostering education of health equity by forming communities of practice groups among patient organizations.' Other notable performers include AstraZeneca for policy support, Eli Lilly and Company for neurology groups, Merck for non-disease-specific groups, and Bristol Myers Squibb for immunology groups. 'The Advocate: Supporting the Patient Voice's goal is to understand the relationship between advocates and the pharmaceutical industry, ensuring that patients remain at the center of all healthcare decisions,' the report states. #patientadvocacy #patientcentric #pharmaceuticalindustry The Brooks Group, Inc.

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

Sandpiper Health's latest Patient Advocacy Group (PAG) survey reveals that many respondents view research and development (R&D) as the most significant aspect of the pharmaceutical industry’s role in healthcare. However, they also advocate for greater transparency and involvement in the drug development and decision-making processes. Effective #communication is key to bridging the gap between the pharmaceutical industry and PAGs, ultimately leading to more #patientcenteredcare. Download your copy of the Patient Advocacy Insights Report to learn more https://lnkd.in/gpsAgCRT #Healthcare #HealthcareCommunications #PatientAdvocacy #PatientVoice Sarada Chellam Vincent Pung Eddie M.

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!